{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:29:32Z","timestamp":1783960172864,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is rare in young patients (age &lt;40 years at diagnosis), with a prevalence of &lt;0.3%, representing ~2% of all patients with MGUS. We hypothesized that MGUS detected in young patients may be associated with a higher risk of progression. We examined 249 patients with MGUS\u2009&lt;\u200940 years old. Among these, 135 patients had immune-related conditions, including infections, autoimmune and inflammatory disorders at the time of diagnosis of MGUS. The risk of progression to multiple myeloma or a related disorder at 5 years and 10 years was 6.0% and 13.8%, respectively. The size of M protein was a significant risk factor for progression (HR 4.2, 95% CI 2.2\u20137.9). There was a trend that the risk of progression was higher in patients without immune-related conditions (HR 2.36, 95% CI 0.85\u20136.52, <jats:italic>p<\/jats:italic>\u2009=\u20090.088). The M protein resolved in 36 (14%) patients, with a greater likelihood of resolution in patients with immune-related conditions (RR 1.9, 95% CI 1.02\u20133.6). Young patients with MGUS have a similar risk of progression as older patients, 1.4% per year. Over 50% are diagnosed in the setting of immune-related disorders. Patients with immune-related disorders may have a lower risk of progression.<\/jats:p>","DOI":"10.1038\/s41408-021-00406-6","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T21:23:32Z","timestamp":1612905812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-2251","authenticated-orcid":false,"given":"Li","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"406_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564\u2013569 (2002).","journal-title":"N. Engl. J. Med."},{"key":"406_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle, R. A. et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378, 241\u2013249 (2018).","journal-title":"N. Engl. J. Med."},{"key":"406_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.97","volume":"7","author":"O Landgren","year":"2017","unstructured":"Landgren, O. et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10\u201349 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 7, e618 (2017).","journal-title":"Blood Cancer J."},{"key":"406_CR4","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"406_CR5","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1182\/blood-2011-04-347559","volume":"118","author":"EK Lindqvist","year":"2011","unstructured":"Lindqvist, E. K. et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118, 6284\u20136291 (2011).","journal-title":"Blood"},{"key":"406_CR6","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","volume":"111","author":"LM Brown","year":"2008","unstructured":"Brown, L. M., Gridley, G., Check, D. & Landgren, O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111, 3388\u20133394 (2008).","journal-title":"Blood"},{"key":"406_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","volume":"23","author":"CM McShane","year":"2014","unstructured":"McShane, C. M. et al. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol., Biomarkers Prevent. 23, 332\u2013342 (2014).","journal-title":"Cancer Epidemiol., Biomarkers Prevent."},{"key":"406_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1756-8722-5-59","volume":"5","author":"K Hemminki","year":"2012","unstructured":"Hemminki, K. et al. Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J. Hematol. Oncol. 5, 59\u201359 (2012).","journal-title":"J. Hematol. Oncol."},{"key":"406_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s10067-010-1417-3","volume":"29","author":"JW Choi","year":"2010","unstructured":"Choi, J. W., Han, S. W., Kwon, K. T. & Kim, G. W. Early onset multiple myeloma in a patient with systemic lupus erythematosus: a case report and literature review. Clin. Rheumatol. 29, 1323\u20131326 (2010).","journal-title":"Clin. Rheumatol."},{"key":"406_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"406_CR11","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3324\/haematol.2010.024778","volume":"95","author":"T Rasmussen","year":"2010","unstructured":"Rasmussen, T. et al. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica 95, 1730\u20131737 (2010).","journal-title":"Haematologica"},{"key":"406_CR12","doi-asserted-by":"publisher","unstructured":"Nair, H. S., Knight, S. R., McKenzie, C., MacDonald, A. J. & Macdonald, A. Age at death and the effect of lead-time bias in patients with colorectal cancer: a 10-year follow-up. Colorectal Dis. 21, 775\u2013781 https:\/\/doi.org\/10.1111\/codi.14602 (2019).","DOI":"10.1111\/codi.14602"},{"key":"406_CR13","first-page":"665","volume":"41","author":"GB Hutchison","year":"1968","unstructured":"Hutchison, G. B. & Shapiro, S. Lead time gained by diagnostic screening for breast cancer. J. Natl Cancer Inst. 41, 665\u2013681 (1968).","journal-title":"J. Natl Cancer Inst."},{"key":"406_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbacli.2016.05.004","volume":"6","author":"A Shimanovsky","year":"2016","unstructured":"Shimanovsky, A., Alvarez Argote, J., Murali, S. & Dasanu, C. A. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 6, 12\u201318 (2016).","journal-title":"BBA Clin."},{"key":"406_CR15","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2012-12-471888","volume":"121","author":"BA Walker","year":"2013","unstructured":"Walker, B. A. et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121, 3413\u20133419 (2013).","journal-title":"Blood"},{"key":"406_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker, B. A. et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28, 384\u2013390 (2014).","journal-title":"Leukemia"},{"key":"406_CR17","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"406_CR18","doi-asserted-by":"publisher","first-page":"106333","DOI":"10.18632\/oncotarget.22462","volume":"8","author":"CC Widmer","year":"2017","unstructured":"Widmer, C. C., Balabanov, S., Schanz, U. & Theocharides, A. P. A. Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease. Oncotarget 8, 106333\u2013106341 (2017).","journal-title":"Oncotarget"},{"key":"406_CR19","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1515\/cclm-2018-0445","volume":"56","author":"D Enko","year":"2018","unstructured":"Enko, D., Emhofer, J., Farid, G. & Kriegshauser, G. Transient monoclonal gammopathy in a 2-year-old child with combined viral and bacterial infection. Clin. Chem. Lab. Med. 56, e310\u2013e312 (2018).","journal-title":"Clin. Chem. Lab. Med."},{"key":"406_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.humpath.2017.11.012","volume":"75","author":"JL Conant","year":"2018","unstructured":"Conant, J. L., Rabinowitz, I. & Zhang, Q. Y. Transient monoclonal gammopathy induced by Candida fungemia. Hum. Pathol. 75, 154\u2013158 (2018).","journal-title":"Hum. Pathol."},{"key":"406_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1309\/AJCPT6OWWMHITA1Y","volume":"138","author":"DL Murray","year":"2012","unstructured":"Murray, D. L. et al. Laboratory persistence and clinical progression of small monoclonal abnormalities. Am. J. Clin. Pathol. 138, 609\u2013613 (2012).","journal-title":"Am. J. Clin. Pathol."},{"key":"406_CR22","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s10067-018-4064-8","volume":"37","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. Monoclonal gammopathy in rheumatic diseases. Clin. Rheumatol. 37, 1751\u20131762 (2018).","journal-title":"Clin. Rheumatol."},{"key":"406_CR23","first-page":"185","volume":"73","author":"A Presle","year":"2015","unstructured":"Presle, A. et al. An acute monoclonal gammopathy? Ann. Biol. Clin. 73, 185\u2013189 (2015).","journal-title":"Ann. Biol. Clin."},{"key":"406_CR24","first-page":"257","volume":"16","author":"RE Mass","year":"1962","unstructured":"Mass, R. E. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother. Rep. 16, 257\u2013259 (1962).","journal-title":"Cancer Chemother. Rep."},{"key":"406_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","volume":"98","author":"N Burwick","year":"2019","unstructured":"Burwick, N. & Sharma, S. Glucocorticoids in multiple myeloma: past, present, and future. Ann. Hematol. 98, 19\u201328 (2019).","journal-title":"Ann. Hematol."},{"key":"406_CR26","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1182\/blood-2007-11-124156","volume":"112","author":"S Sharma","year":"2008","unstructured":"Sharma, S. & Lichtenstein, A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 112, 1338\u20131345 (2008).","journal-title":"Blood"},{"key":"406_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1157\/13123188","volume":"208","author":"ME Gonzalez Garcia","year":"2008","unstructured":"Gonzalez Garcia, M. E. et al. A series of 618 cases of monoclonal gammopathies of undetermined significance: predictive factors of disappearance of monoclonal component or evolution to malignant gammopathies. Rev. Clin. Espanola 208, 288\u2013294 (2008).","journal-title":"Rev. Clin. Espanola"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00406-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:39:17Z","timestamp":1669909157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00406-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00406-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"17 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"26"}}